Skip to main
MDT

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 25%
Buy 40%
Hold 35%
Sell 0%
Strong Sell 0%

Bulls say

Medtronic is a well-established medical device company with a diverse product portfolio and strong performance in key markets, including the United States, Western Europe, and Japan. Its successful Symplicity Spyral Renal Denervation System and undervalued stock position suggest potential for significant future growth, though potential risks and challenges from competition and market conditions should be closely monitored.

Bears say

Medtronic is currently facing several key risks that could impact its future growth and profitability, including potential market share losses to competitor product launches, disappointing sales from new products, lower-than-expected margins, and negative currency impacts. Additionally, the company's global presence makes it susceptible to macroeconomic volatility, and its capital allocation strategy may face challenges if management is unable to make effective investments. Furthermore, the separation of its Diabetes business could create uncertainties and risks, and potential underperformance in upcoming clinical trials for key devices may also impact future earnings. Despite the company's strong portfolio and expected revenue growth, these risks contribute to our negative outlook on Medtronic's stock.

Medtronic (MDT) has been analyzed by 20 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 40% recommend Buy, 35% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 20 analysts, Medtronic (MDT) has a Buy consensus rating as of Jul 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.